189 results
Page 2 of 10
8-K
EX-99.1
t43iv qjns9i8e8x
13 Jul 23
Regulation FD Disclosure
12:00am
8-K
cigclyqml m7y02cqsd
13 Jul 23
Regulation FD Disclosure
12:00am
8-K
EX-99.1
ny4 1lui2g8sbh3
10 May 23
Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
4:07pm
8-K
EX-99.1
fmch2mqwp r1w2uqqmc
2 May 23
Preliminary results demonstrate a durable complete response at starting dose level in elderly subject
8:35am
8-K
EX-99.1
zh8l3q
21 Dec 22
Regulation FD Disclosure
8:25am
8-K
EX-99.1
8096hq
15 Dec 22
Preliminary efficacy updated to 80% overall response rate (ORR) demonstrated in single agent AML trial following database lock
8:37am
8-K
EX-99.1
7bbe6v0kl7y
7 Dec 22
Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme
8:45am
8-K
EX-99.1
fin6pbcq
10 Nov 22
Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
4:11pm
8-K
EX-99.1
suexwj6o 3tfvcss5j
14 Oct 22
Moleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
8:40am
8-K
EX-99.1
v7dft4abwnmn59 pv01
27 Sep 22
Regulation FD Disclosure
8:36am
8-K
EX-99.1
dsln16vf8sva
19 Aug 22
Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
8:40am
8-K
7rktpe 6jbk
19 Aug 22
Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
8:40am
8-K
EX-99.1
d09nap65 m0jvn7i1acf
15 Aug 22
Moleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update
8:48am
8-K
EX-99.1
is27v
28 Jul 22
Regulation FD Disclosure
8:35am
8-K
ehbobpfggq5j k7f
28 Jul 22
Regulation FD Disclosure
8:35am
8-K
EX-99.1
pehwa5
8 Jul 22
Cohort in Phase 1a Clinical Trial of WP1122 in the UK
8:37am